ESC2026

News

ESC26: Can Arrowhead pierce Ionis' triglyceride armour?

Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.

News

ESC26: AZ's relaxin agonist shows promise in heart failure

An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients with heart failure.

News

ESC26: Cytokinetics' big data reveal for Myqorzo impresses

Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of Myqorzo in non-obstructive hypertrophic cardiomyopathy at ESC 2026.

News

ESC26: Heart attack reclassification rights gender imbalance

New definitions of myocardial infarction released at ESC 2026 recognise that there are different causes - and could lead to better treatment of women.

News

ESC26: Isomab safety evidence on blood vessel growth for CAD

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

ESC26: Can Arrowhead pierce Ionis' triglyceride armour?

ESC26: AZ's relaxin agonist shows promise in heart failure

ESC26: Cytokinetics' big data reveal for Myqorzo impresses

ESC26: Heart attack reclassification rights gender imbalance

ESC26: Isomab safety evidence on blood vessel growth for CAD

AI, start-ups, and the future of human health: AION Labs’ Ma...

Discover a new era of healthcare panel engagement: Grounded ...

ESC2026

Editor's Picks